WGS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GeneDx Holdings Corp (WGS) is not a strong buy for a beginner, long-term investor at this time. Despite positive analyst ratings and potential growth opportunities, the stock's technical indicators are bearish, insiders are selling heavily, and financial performance shows significant net income and EPS declines. The lack of recent positive news or strong proprietary trading signals further supports a hold recommendation.
The stock is exhibiting bearish technical indicators. The MACD is negatively expanding (-0.87), the RSI is neutral at 20.335, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with S1 at 63.276 and S2 at 58.726. The pre-market price is down 1.32%, further indicating weakness.
The company is pursuing large new market opportunities and expanding its sales force, which could drive growth in 2026.
Insider selling has increased by 399.11% over the last month, indicating potential lack of confidence from internal stakeholders. The stock has a 60% chance to decline by 2% in the next day and 6.83% in the next month. Competitor Natera's recent product launch may also intensify competition.
In Q4 2025, revenue increased by 26.50% YoY to $120,989,000. However, net income dropped significantly to -$17,666,000 (-424.86% YoY), and EPS fell to -0.61 (-405.00% YoY). Gross margin slightly improved to 69.65% (+0.62% YoY), but overall financial performance remains weak.
Analysts maintain a generally positive outlook with buy ratings. However, several firms have lowered their price targets recently, citing competitive dynamics and noisy market conditions. Price targets range from $130 to $170, with a median target of $153.
